EP300 and prostate carcinoma: The use of immunochemistry in biopsies of castration-sensitive prostate cancer proved that neither the nuclear CBP protein nor the nuclear p300 protein expression was significantly (p = 0.28) altered as the prostate tumors progressed from castration-sensitive to castration-resistant prostate cancer.